Policy Support
2 Insights with Topic: Policy Support
The recent sell-off in China’s new-economy sector exposes a sharp disconnect between market sentiment and robust operational fundamentals. Despite 'de-CATLization' fears drove steep valuation corrections, CATL expanded its market share, anchored by global scale, brand equity, and a high-margin energy storage business. Beyond batteries, global biotech licensing breakthroughs and localized AI hardware demand provide powerful tailwinds across innovative segments in China. Meanwhile with the premium in CATL-H over A-share, CATL-A which Premia China New Economy ETF allocates to, has also become one of the few if not only overweight-rated stock in Chinese battery universe for most analysts and allocators while CATL-H being neutral-rated. In this article, we discuss how, with valuations compressed, current level of Premia China New Economy ETF offers a timely entry point to accumulate market leaders on weakness.
Oct 22, 2026
China's biopharmaceutical industry is undergoing a landmark transformation, emerging from a period of profound recalibration to establish itself as a global powerhouse. Propelled by its talent, patient access, cost-efficient infrastructure, and catalysed by comprehensive government policies aimed at supporting the innovative drug value chain, the sector is experiencing a broad-based resurgence, with results beginning to show in earnings and valuations in the first half of the year. The journey, however, is just beginning, fueled by the impending global patent cliff and its strong value proposition: delivering high-quality, innovative medicines at an accelerated pace. This capability ensures China's biopharma sector an indispensable player in the global market, even in the face of possible geopolitical headwinds. In this article, we discuss about the leading innovators in the homegrown biotech landscape—companies well-represented in our Premia China New Economy ETF (3173/9173 HK) and Premia China STAR50 ETF (3151/9151/83151 HK), which have outperformed multiple benchmarks year-to-date and will continue to drive alpha returns for global investors, propelled by a revaluation trend driven by domestic policy tailwinds, strong external partnerships and a rising market value.
Oct 02, 2025